ijms-logo

Journal Browser

Journal Browser

Cardiometabolic Disease: Molecular Biomarkers and Treatment Strategies

Special Issue Editor


E-Mail Website
Guest Editor
Department of Nutritional Sciences, College of Human Sciences, Auburn University, Auburn, AL 36849, USA
Interests: cardiometabolic diseases; metabolic pathways; metabolic dysregulation

Special Issue Information

Dear Colleagues,

This Special Issue addresses cardiometabolic diseases (CMD), including cardiovascular disease and diabetes, which remain leading causes of death worldwide. Traditional clinical measures often fall short in early detection and risk prediction. We focus on recent advances in molecular biomarkers identified through cutting-edge omics technologies, including proteomics, metabolomics, genomics, and transcriptomics. These biomarkers reveal the underlying molecular and metabolic disruptions that drive CMD, enabling earlier diagnosis, better risk assessment, and more accurate prognosis.

The Issue highlights innovative treatment strategies guided by these molecular insights, emphasizing personalized medicine approaches that can slow or reverse disease progression. We showcase research integrating bioinformatics and machine learning for biomarker discovery, studies examining how CMD develops at the molecular level, and investigations into how lifestyle factors, such as diet and exercise, influence disease risk through molecular pathways.

Our goal is to present multidisciplinary research spanning molecular biology to clinical applications that advances early intervention and tailored therapies. This Issue addresses the urgent need for validated molecular biomarkers and effective treatments that reduce the global burden of cardiometabolic diseases across diverse populations.

Dr. Mehrnaz Abbasi
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cardiometabolic diseases
  • molecular biomarkers
  • omics technologies
  • personalized medicine
  • early detection
  • machine learning
  • disease progression
  • metabolic pathways
  • transcriptomics
  • genomic profiling
  • bioinformatics
  • therapeutic targets
  • metabolic dysregulation

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

21 pages, 445 KB  
Review
Operon™ Platform-Enabled for Cardiometabolic Biomarker Screening and Precision Treatment Strategies: A Type 2 Diabetes-Centered Review with Cardiovascular Extension
by Ian Jenkins, Krista Casazza, Vaishnavi Narayan, Waldemar Lernhardt, Valentina Savich, Jayson Uffens, Pedro Gutierrez-Castrellon and Jonathan R. T. Lakey
Int. J. Mol. Sci. 2026, 27(9), 3969; https://doi.org/10.3390/ijms27093969 - 29 Apr 2026
Viewed by 190
Abstract
Cardiometabolic diseases, encompassing obesity, insulin resistance, type 2 diabetes (T2D), metabolic dysfunction-associated steatotic liver disease (MASLD), hypertension, and atherosclerotic cardiovascular disease (ASCVD), represent a vast continuum driven by multi-organ network dysregulation. Clinical risk assessment remains dominated by late-stage measures (e.g., fasting glucose, HbA1c, [...] Read more.
Cardiometabolic diseases, encompassing obesity, insulin resistance, type 2 diabetes (T2D), metabolic dysfunction-associated steatotic liver disease (MASLD), hypertension, and atherosclerotic cardiovascular disease (ASCVD), represent a vast continuum driven by multi-organ network dysregulation. Clinical risk assessment remains dominated by late-stage measures (e.g., fasting glucose, HbA1c, standard lipids). While these assessments predominate the literature and clinical trial endpoints, each incompletely capture early mechanistic risk, inter-individual heterogeneity, and differential response to interventions. Multiomics (genomics, epigenomics, transcriptomics, proteomics, metabolomics, lipidomics, microbiomics, and extracellular vesicle/exosome cargo profiling) expands the biomarker landscape but introduces translational barriers: high dimensionality, cohort heterogeneity, limited causal inference, and insufficient validation pipelines. AI-driven systems biology platforms can support cardiometabolic biomarker discovery and therapeutic translation by enabling systems-level biological inference across heterogeneous datasets, prioritizing mechanism and traceability over purely correlation-based models. GATC Health’s Operon™ platform is described as a proprietary, AI-driven internal scientific computing platform designed to support therapeutic discovery and development decision-making across the pharmaceutical lifecycle, including evaluation of drug efficacy, safety, off-target effects, pharmacokinetics (PK), pharmacodynamics (PD), and overall development risk. Operon evolved from earlier generations of GATC Health’s internal multiomic modeling systems (formerly referred to as the Multiomics Advanced Technology, MAT) and incorporates expanded data types, orchestration layers, validation workflows, and productization frameworks. Operon is operated by GATC scientists and generates structured, productized outputs (e.g., formal assessments, analyses, and decision frameworks) that are reviewed by experts. Operon methodologies have undergone internal validation and independent academic evaluation under blinded conditions, with reported classification performance (true positive rate 86% and true negative rate 91%) in controlled evaluation settings; these performance metrics should not be interpreted as guarantees of clinical success. This review provides a T2D-centered cardiometabolic biomarker landscape with cardiovascular extension and outlines how Operon-enabled multiomic integration and scenario-based simulation can support early screening, endotype stratification, mechanistic interpretation, and precision intervention design, including AI-guided polypharmacology strategies. Full article
Show Figures

Figure 1

Back to TopTop